These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19825907)

  • 1. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
    Umene-Nakano W; Yoshimura R; Ueda N; Suzuki A; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    J Psychopharmacol; 2010 Dec; 24(12):1764-71. PubMed ID: 19825907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system.
    Brunoni AR; Kemp AH; Shiozawa P; Cordeiro Q; Valiengo LC; Goulart AC; Coprerski B; Lotufo PA; Brunoni D; Perez AB; Fregni F; Benseñor IM
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1530-40. PubMed ID: 23615118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD).
    Katsuki A; Yoshimura R; Kishi T; Hori H; Umene-Nakano W; Ikenouchi-Sugita A; Hayashi K; Atake K; Iwata N; Nakamura J
    CNS Spectr; 2012 Sep; 17(3):155-63. PubMed ID: 22883353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.
    Durham LK; Webb SM; Milos PM; Clary CM; Seymour AB
    Psychopharmacology (Berl); 2004 Aug; 174(4):525-9. PubMed ID: 12955294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder.
    Nishioka G; Yashima H; Kiuchi Y; Nakamura S; Oyamada H; Ishii M; Kudo I
    Hum Psychopharmacol; 2013 Nov; 28(6):576-85. PubMed ID: 24519691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter genotype and function in relation to antidepressant response in Koreans.
    Myung W; Lim SW; Kim S; Kim H; Chung JW; Seo MY; Kim JW; Carroll BJ; Kim DK
    Psychopharmacology (Berl); 2013 Jan; 225(2):283-90. PubMed ID: 22885912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.
    Jarčušková D; Tkáč I; Hlaváčová N; Yaluri AS; Kozárová M; Habalová V; Klimčáková L; Židzik J; Javorský M; Bednářová A
    BMC Psychiatry; 2024 Oct; 24(1):690. PubMed ID: 39407134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients.
    Oz MD; Baskak B; Uckun Z; Artun NY; Ozdemir H; Ozel TK; Ozguven HD; Suzen HS
    Pharmacogenomics J; 2020 Jun; 20(3):443-450. PubMed ID: 31792367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
    Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: report of eleven cases.
    Schillani G; Capozzo MA; Aguglia E; De Vanna M; Grassi L; Conte MA; Giraldi T
    Tumori; 2008; 94(4):563-7. PubMed ID: 18822694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
    JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients.
    Yoshimura R; Kishi T; Suzuki A; Umene-Nakano W; Ikenouchi-Sugita A; Hori H; Otani K; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1022-5. PubMed ID: 21338649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.
    Yukimasa T; Yoshimura R; Tamagawa A; Uozumi T; Shinkai K; Ueda N; Tsuji S; Nakamura J
    Pharmacopsychiatry; 2006 Mar; 39(2):52-9. PubMed ID: 16555165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression.
    Tatham EL; Hall GB; Clark D; Foster J; Ramasubbu R
    Eur Arch Psychiatry Clin Neurosci; 2017 Mar; 267(2):135-147. PubMed ID: 27277475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Atake K; Nakamura J
    Hum Psychopharmacol; 2013 Sep; 28(5):466-70. PubMed ID: 23813968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
    Lee SH; Choi TK; Lee E; Seok JH; Lee SH; Lee HS; Kim SJ
    Neuropsychobiology; 2010 Aug; 62(3):198-206. PubMed ID: 20664233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    Manoharan A; Shewade DG; Rajkumar RP; Adithan S
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.